How to buy Ideaya Biosciences stock (IDYA)

Ideaya Biosciences is a biotechnology business based in the US. Ideaya Biosciences shares (IDYA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.61 – an increase of 1.67% over the previous week. Ideaya Biosciences employs 124 staff and has a trailing 12-month revenue of around $3.9 million.

Our top picks for where to buy Ideaya Biosciences stock

Buy Ideaya Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ideaya Biosciences stock price (NASDAQ: IDYA)

Use our graph to track the performance of IDYA stocks over time.

Ideaya Biosciences shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$25.61
52-week range	$24.48 - $47.74
50-day moving average more info button	$28.65
200-day moving average more info button	$36.52
Wall St. target price	$55.79
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.33

Is it a good time to buy Ideaya Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ideaya Biosciences price performance over time

Historical closes compared with the close of $25.61 from 2024-12-20

1 week (2024-12-13)	1.67%
1 month (2024-11-22)	-4.40%
3 months (2024-09-20)	-26.83%
6 months (2024-06-21)	-30.77%

1 year (2023-12-22)	-26.11%
2 years (2022-12-22)	50.65%
3 years (2021-12-22)	9.96%
5 years (2019-12-20)	181.74%

Ideaya Biosciences financials

Revenue TTM	$3.9 million
Gross profit TTM	$-38,605,000
Return on assets TTM	-15.85%
Return on equity TTM	-21.1%
Profit margin	0%
Book value	$13.67
Market Capitalization more info button	$2.2 billion

TTM: trailing 12 months

Ideaya Biosciences share dividends

We're not expecting Ideaya Biosciences to pay a dividend over the next 12 months.

Ideaya Biosciences share price volatility

Over the last 12 months, Ideaya Biosciences's shares have ranged in value from as little as $24.475 up to $47.735. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ideaya Biosciences's is 0.858. This would suggest that Ideaya Biosciences's shares are less volatile than average (for this exchange).

Ideaya Biosciences overview

IDEAYA Biosciences, Inc. , a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc. , Novartis International Pharmaceuticals Ltd. , Amgen Inc.

Frequently asked questions

null
What percentage of Ideaya Biosciences is owned by insiders or institutions?
Currently 1.036% of Ideaya Biosciences shares are held by insiders and 111.287% by institutions. How many people work for Ideaya Biosciences?
Latest data suggests 124 work at Ideaya Biosciences. When does the fiscal year end for Ideaya Biosciences?
Ideaya Biosciences's fiscal year ends in December. Where is Ideaya Biosciences based?
Ideaya Biosciences's address is: 7000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Ideaya Biosciences's ISIN number?
Ideaya Biosciences's international securities identification number is: US45166A1025 What is Ideaya Biosciences's CUSIP number?
Ideaya Biosciences's Committee on Uniform Securities Identification Procedures number is: 45166A102